4DMedical (ASX:4DX) said a study evaluating its CT:VQ imaging product, published in the American Journal of Respiratory and Critical Care Medicine, shows that CT:VQ-guided patient selection would deliver a 76% response rate to lung volume reduction surgery (LVRS), compared with the current rate of 46%, according to a Tuesday Australian bourse filing.

The company said CT:VQ derives functional ventilation and perfusion information from existing non-contrast CT scans, with improved pre-operative patient selection strengthening the economics of LVRS programs for hospitals by concentrating surgical resources on patients most likely to benefit.

The company's shares were up 3% in recent Tuesday trade.